Monday 19 August 2013

Drugs that target FleN could lead to anti-biofilm therapies

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Cystic Fibrosis
Article Date: 19 Aug 2013 - 0:00 PDT Current ratings for:
Drugs that target FleN could lead to anti-biofilm therapies
not yet ratednot yet rated

The evolution of hyperswarming, pathogenic bacteria might sound like the plot of a horror film, but such bugs really have repeatedly evolved in a lab, and the good news is that they should be less of a problem to us than their less mobile kin. That's because those hyperswarmers, adorned with multiple whipping flagella, are also much worse at sticking together on surfaces in hard-to-treat biofilms. They might even help us figure out a way to develop anti-biofilm therapies for use in people with cystic fibrosis or other conditions, say researchers who report their findings in Cell Reports, a Cell Press publication.

The findings are also a textbook example of real-time experimental evolution. What's more, says Joao Xavier of Memorial Sloan Kettering Cancer Center, they are a "unique example of strikingly parallel molecular evolution."

In other words, the evolution that he and his team witnessed was repeatable, all the way down to the molecular level.

The researchers didn't set out with the goal to evolve hyperswarmers, but they did passage Pseudomonas aeruginosa on special plates over a period of days. On those plates, bacteria that could spread out had an advantage in harvesting nutrients from the surface, and within a matter of days, some of those bacteria started hyperswarming.

Investigation of the bacteria showed that P. aeruginosa gained its hyperswarming ability through a single point mutation in a flagellar synthesis regulator (FleN). As a result, the bacteria, which usually have one single flagellum, were locked into a multi-flagellated state. They became better at moving around to cover a surface, but much worse at forming densely packed, surface-attached biofilm communities. All told, the researchers saw this new ability independently arise 20 times.

"The fact that the molecular adaptations were the same in independent lineages suggests evolution may be, to some extent, predictable," says Xavier.

The findings may be very important because biofilms are a major problem in clinical settings. Infectious biofilms are hard to remove and difficult to kill with antibiotics. Drugs that target FleN or that otherwise make bacteria better at spreading out and worse at settling down could leave them more vulnerable to antibiotics and easier to get rid of.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Press, Cell. "Drugs that target FleN could lead to anti-biofilm therapies." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
19 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Drugs that target FleN could lead to anti-biofilm therapies'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment